But, as Celyad bows out, how do you compete in a field as crowded as this?
Evaluate Vantage's coverage of the Ash 2022 congress.
Meanwhile, there was bad blood between cell therapy players and their investors.
Novartis and Gracell’s two-day manufactured Cars do not solve cell therapy’s biggest bottleneck – yet.
Talquetamab gets top billing in Ash’s press programme, but the data raise important issues about the role of targeting GPRC5D.
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.